Announcement: CU Denver is Celebrating 50 Years
Whether you’re an alumnus, current student, member of the faculty and staff, donor, or neighbor, you’re a valuable part of the CU Denver community. Help us celebrate the last 50 years and a future that works for all.
Learn More
SPARK 18 | Learning from Successful Academic Entrepreneurs
|
05:00 PM - 07:00 PM
Room Number: 1400
Education I
13070 East 19th Avenue
Aurora, CO
Room Number: 1400
Education I
13070 East 19th Avenue
Aurora, CO
RSVP Here
Gain practical insights into transnational research, moving an idea from lab to patients, what it takes to be an academic entrepreneur, how to juggle multiple priorities, key to success and much more...
Presented by:
Distinguished Professor and the Chief Scientific Officer of the BioFrontiers Institute at
the University of Colorado Boulder. She was recruited to be Chair of MCDB in 1995. She
received her Bachelor’s degree from Cornell University, her PhD from Yale University
and did post-doctoral training at Rockefeller University. She joined the faculty at Albert
Einstein College of Medicine in New York in 1981 and remained there until moving to
Colorado in 1995. She co-founded Myogen, Inc. which was sold to Gilead
Pharmaceuticals. She was also a co-founder of Hiberna, Inc, and more recently of
MyoKardia, Inc, a publicly traded company founded to develop therapeutics for
inherited cardiomyopathies. She is a Fellow of the AAAS, former MERIT Awardee of the
NIH, Established Investigator of the American Heart Association and was recently
elected to the American Academy of Arts and Sciences and the National Academy of
Inventors. The interests of Dr. Leinwand’s laboratory are the genetics and molecular
physiology of inherited diseases of the heart and how gender and diet modify the heart.
The study of these diseases has required multidisciplinary approaches, involving
molecular biology, mouse genetics, mouse cardiac physiology, and the analysis of
human tissues. Her teaching was recognized by funding from the Howard Hughes
Medical Institute’s Professor Program.
Gain practical insights into transnational research, moving an idea from lab to patients, what it takes to be an academic entrepreneur, how to juggle multiple priorities, key to success and much more...
Presented by:
Leslie Leinwand, PhD
CSO, Biofrontiers Institute, CU Boulder
Co-Founder of Myogen
Distinguished Professor and the Chief Scientific Officer of the BioFrontiers Institute at
the University of Colorado Boulder. She was recruited to be Chair of MCDB in 1995. She
received her Bachelor’s degree from Cornell University, her PhD from Yale University
and did post-doctoral training at Rockefeller University. She joined the faculty at Albert
Einstein College of Medicine in New York in 1981 and remained there until moving to
Colorado in 1995. She co-founded Myogen, Inc. which was sold to Gilead
Pharmaceuticals. She was also a co-founder of Hiberna, Inc, and more recently of
MyoKardia, Inc, a publicly traded company founded to develop therapeutics for
inherited cardiomyopathies. She is a Fellow of the AAAS, former MERIT Awardee of the
NIH, Established Investigator of the American Heart Association and was recently
elected to the American Academy of Arts and Sciences and the National Academy of
Inventors. The interests of Dr. Leinwand’s laboratory are the genetics and molecular
physiology of inherited diseases of the heart and how gender and diet modify the heart.
The study of these diseases has required multidisciplinary approaches, involving
molecular biology, mouse genetics, mouse cardiac physiology, and the analysis of
human tissues. Her teaching was recognized by funding from the Howard Hughes
Medical Institute’s Professor Program.
Michael Bristow, MD PhD
Professor of Medicine-Cardiology CU Anschutz
Co-founder of Myogen
Michael R. Bristow, MD, PhD, is currently Professor of Medicine (Cardiology) at the University of Colorado, Anschutz Medical Center in Aurora, CO. He is a fellow of the American College of Cardiology, a founding member of the Heart Failure Society of America, and a member of many other professional societies and editorial boards. Dr. Bristow has authored over 400 peer reviewed papers and chapters on heart failure and other cardiovascular diseases, was instrumental in elucidating key molecular mechanisms underlying heart failure and the use of β‐blockers for its treatment, has identified and characterized numerous genetic polymorphisms that affect cardiovascular drug action, and and is currently engaged in the development of pharmacogenetically targeted cardiovascular drugs such as bucindolol (Gencaro™). He has received many academic and industry honors, including the Therapeutics Frontiers Award by the American college of Clinical Pharmacy for developing -blockade as a treatment for heart failure, the Pharmaceutical Research and Manufacturers of America Clinical Trial Exceptional Service Award for the development of carvedilol (Coreg™) for heart failure, the Lifetime Achievement Award by the Heart Failure Society of America, and Scientist of the Year (2008) by the Colorado Chapter of the ARCS Foundation. Dr. Bristow is the President and CEO of ARCA biopharma, a Broomfield, CO company he founded in 2003 with the mission of developing genetically targeted therapies for heart failure and other cardiovascular diseases. In 2007 he co‐founded Miragen Therapeutics, Inc., a Boulder, CO company dedicated to utilizing the biologic properties of microRNA in developing therapies for cardiovascular diseases. He was also the principal founder and former chief science and medical officer of Myogen, Inc., a Westminster, CO biopharmaceutical company that was acquired by Gilead Sciences, Inc., in 2006.
Add event to: